CULVER CITY, Calif.--(BUSINESS WIRE)--Dec. 19, 2016--
NantKwest (Nasdaq:NK), a pioneering, next generation, clinical-stage
immunotherapy company focused on harnessing the unique power of the
human immune system using natural killer (NK) cells to treat cancer,
infectious diseases and inflammatory diseases today announced that the
company will be hosting an Investor/Analyst Day on January 8th
in San Francisco.
NantKwest will be sharing with analysts and investors a review of the
company’s activities in 2016 and provide an overview for 2017.
At this event, senior management of NantKwest will provide a review of
its ongoing R&D program, as well as provide an in-depth clinical trial
roadmap for the aNK, haNK and taNK clinical programs for 2017.
In addition to senior management presentations, the event will feature
presentations by key opinion leaders in the immunotherapy field.
A webcast of the event will begin at 5:00 PM PT on Sunday, January 8,
2017 and is expected to conclude at 7:30 PT. A link to the live webcast
can be accessed by visiting the Investors page of the company's website.
In addition, a replay of the event will be posted on the website after
the event and will be available for 30 days following the event.
NantKwest (Nasdaq:NK) is a pioneering, next generation, clinical-stage
immunotherapy company focused on harnessing the unique power of our
immune system using natural killer (NK) cells to treat cancer,
infectious diseases and inflammatory diseases. NK cells are the body’s
first line of defense due to the innate ability of NK cells to rapidly
identify and destroy cells under stress, such as cancer or
NantKwest’s unique NK cell-based platform, with the capacity to grow
active killer cells as a biological cancer therapy, has been designed to
induce cell death against cancer or infected cells by three different
modes of action: (1) Direct killing using activated NK cells (aNK) that
release toxic granules directly into the cell through cell to cell
contact, (2) Antibody-mediated killing using haNKs, which are NK cells
engineered to incorporate a high affinity receptor that binds to an
administered antibody, enhancing the cancer cell killing effect of that
antibody, and (3) Targeted activated killing using taNKs, which are NK
cells engineered to incorporate chimeric antigen receptors (CARs) to
target tumor-specific antigens found on the surface of cancer cells.
Our aNK, haNK and taNK platform addresses certain limitations of T cell
therapies including the reduction of risk of serious "cytokine storms"
reported after T cell therapy. As an “off-the-shelf” therapy,
NantKwest's NK cells do not rely on a patient’s own often compromised
immune system. In Phase 1 clinical trials in patients with late stage
cancer, NantKwest's NK cells have been successfully administered as an
outpatient infusion therapy without any reported severe side effects,
even at doses of 10 billion cells.
By leveraging an integrated and extensive genomics and transcriptomics
discovery and development engine, together with a pipeline of multiple,
clinical-stage, immuno-oncology programs that include a Phase 2 trial
for a rare form of melanoma and the planned initiation of a clinical
trial of NK cells targeted to breast cancer, we believe NantKwest is
uniquely positioned to be the premier immunotherapy company and
transform medicine by delivering living drugs in a bag and bringing
novel NK cell-based therapies to routine clinical care. For more
information, please visit www.nantkwest.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20161219005422/en/
Jen Hodson, Public Relations Director
David Pyrce, SVP, Innovation and Chief Commercial Officer